As the WL achieved with the novel obesity pharmacotherapies approaches that of bariatric surgery, we will need to assess whether long-term complications observed after bariatric surgery such as increased risk of osteoporosis, fractures, macro- and micronutrient deficiencies as well as self-harm behaviours will also be present with pharmacotherapy [112, 113]
Retatrutide (LY3437943) is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously that has not received UK marketing authorisation from the MHRA or approval from the EMA
we chose a suitable comparator group
H.et al (2017)
In recent years, basic and clinical studies have shown that GLP-1 is closely related to lipid metabolism, and it can participate in lipid metabolism by inhibiting fat synthesis, promoting fat differentiation, enhancing cholesterol metabolism, and promoting adipose browning